---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-091225"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:56:44.030226+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acurx reports Q2 2022 net loss of $2.6M; Phase 2b trial enrollment continues with site expansion

## Summary
- Net loss $2.6M ($0.26/diluted) for Q2 2022 vs $4.0M ($0.57) a year ago.
- Cash $9.1M at June 30, 2022, down from $13.1M at Dec 31, 2021.
- Phase 2b CDI trial enrollment slower; up to 30 clinical sites being added.
- Raised $4.225M via July 2022 direct offering to institutional investor and executives.
- Ibezapolstat showed favorable killing kinetics vs vancomycin in lab studies.

## SEC filing metadata
- accession: 0001104659-22-091225
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/0001104659-22-091225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/tm2223469d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-091225
- JSON: https://secwatch.observer/filing/0001104659-22-091225.json
- Plain text: https://secwatch.observer/filing/0001104659-22-091225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.